Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The primary purpose of this study is to determine whether Nivolumab will improve disease-free
survival compared with placebo.
Phase
Phase 3
Funding Agency/Sponsor
Industrial
Disease
Stomach and Esophageal Cancer
Enrollment Eligibility
Inclusion Criteria:
- Diagnosed with Stage II/III carcinoma of the esophagus or gastroesophageal junction
- Completed pre-operative chemo radiotherapy followed by surgery
- Diagnosed with residual pathologic disease after being surgically rendered free of
disease with negative margins following complete resection
Exclusion Criteria:
- Diagnosed with cervical esophageal carcinoma
- Diagnosed with Stage IV resectable disease
- Did not receive concurrent chemoradiotherapy prior to surgery
- Participants who have received a live/attenuated vaccine within 30 days of the first
treatment
Other protocol defined Inclusion/exclusion criteria could apply